Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 2 6Phase 1 5Phase 3 2Phase NA 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Leukemia 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Fatigue 1Congenital Abnormalities 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3Ciprofloxacin 3Immunoglobulins, Intravenous 2Dexamethasone 2Amoxicillin-Potassium Clavulanate Combination 2daratumumab 1Thalidomide 1MAGEA3 protein, human 1Lenalidomide 1Immunoglobulins 1Clavulanic Acid 1Calcium Dobesilate 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasms, Plasma Cell × Calcium Dobesilate × Clear all
NCT00038090 2018-10-31

Thalidomide-Dexamethasone for Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2/3 Completed
83 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡